Research programme: kinesin spindle protein inhibitors - Cytokinetics/GlaxoSmithKline

Drug Profile

Research programme: kinesin spindle protein inhibitors - Cytokinetics/GlaxoSmithKline

Alternative Names: GSK-295; KSPA-1

Latest Information Update: 28 Jan 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cytokinetics
  • Developer Cytokinetics; GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 30 Sep 2008 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 01 Sep 2008 Interim pharmacokinetics data from a preclinical trial in Cancer presented at the 236th American Chemical Society National Meeting (236th-ACS-2008)
  • 19 Jun 2008 Cytokinetics and GlaxoSmithKline extend their collaboration for a third time
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top